An endoglycosidase from a highly metastatic variant (ESb) of a low-metastatic T-cell lymphoma (Eb) has previously been shown to degrade heparan sulphate-containing material produced by vascular endothelial cells. Such enzyme activity was not detected in the parental cell line Eb . This supports the concept that tumour cellassociated enzymes are necessary for the penetration of blood vessel walls, as an early decisive step of metastasis (Pauli et al., 1983; Kramer & Vogel, 1984; Becker et al., 1986) . We have now studied the substrate specificity of the endoglycosidase described for the Eb/ESb tumour system on purified proteoglycans. The experimental system described here consisted of the murine methylcholanthrene-induced, low metastatic T lymphoma Eb, its highly metastatic variant ESb (Schirrmacher et al., 1979) and a low-metastatic variant of ESb, ESb-MP, which was selected for its plastic-adherent growth in vitro (Fogel et al., 1983) . Eb and ESb cells were distinguished from each other by their specific expression of differentiation antigens (Altevogt et al., 1982) , tumourassociated transplantation antigens (TATA) and cell surface glycoconjugates (Schwartz et al., 1984; whereas the variant ESb-MP is more closely related to the cell line ESb -both cell types express identical differentiation antigens and TATA (Fogel et al., 1983) .
These three cell lines were investigated for their ability to degrade a proteochondroitin sulphate (PCS), a cell surface proteoheparan sulphate (HS I) from bovine aortic endothelial cells which is released into the culture medium by plasma membrane shedding (Keller et al., 1987) and a basement membrane proteoheparan sulphate (HR9-PHS) from HR9-cells (Keller & Furthmayr, 1986) . The two major proteoglycans from endothelial cell conditioned medium, HS I (cell surface proteoheparan sulphate) and the low molecular weight PCS (proteochondroitin sulphate), were isolated by chromatography on Sepharose CL-4B (Figure la) and, in a subsequent step, by chromatography on DEAESephacel (Figure lb) . Finally, the proteoglycans were purified by CsCI density gradient ultracentrifugation (data not shown).
The preparations obtained were characterized by alkali degradation and by digestion with Chondroitinase AC or Heparinase (Figure 2a-c) . These purified substances were used to coat microtitre wells.
Typically, the labelled proteoglycans were bound to the plastic surface with 10% efficiency. The substances could be released from the plastic surface with 7 M urea plus 2% (w/v) SDS. No qualitative difference was observed between the bound fractions and the proteoglycans remaining in the supernatant. However, when proteoglycans were presented in soluble form to the tumour cells, no degradative effect could be observed (data not shown). This may be due to a higher concentration of the substrate when presented in immobilized form.
After incubation of the 3 tumour cell lines on proteoglycancoated plates no degradation of endothelial PCS or HS I by any of the cell lines studied was observed (Figure 2d-k) . Only HR9-PHS was degraded by ESb cells (Figure 21 ). We have repeated the degradation experiments 15 times using proteoglycan samples from 4 independent preparations. In all of these experiments the same degradation pattern was observed. In kinetic experiments ( Figure 3 ) the (35S)-HR9-PHS-coated wells were incubated with suspensions of ESb cells for various times. There was a time dependent, gradual shift towards labelled degradation products of lower molecular weight, which appeared at the V, of the Sepharose CL-6B chromatography column. At no time did we observe compounds of the size of the free glycosaminoglycan chain. From these data, it is suggested that proteolytic degradation of the proteoheparan sulphate, which would result in the release of single peptidoglycosaminoglycans, is minor compared to the digestion of the heparan sulphate polysaceharide portion.
The results presented here essentially confirm those of Vlodavsky and coworkers Bar-Nel et al., 1985) who demonstrated endoglycosidase activity released by ESb in contrast to Eb cells. These authors proposed a sequential degradation of proteoglycans embedded in the extracellular matrix, first by serine-proteases Bar-Ner et al., 1986) producing high molecular sulphate labelled compounds and then by an endoglycosidase degrading these substances to low molecular fragments. This concept does not necessarily contradict our observation that the endoglycosidase alone is capable of the total degradation of the HR9-PHS, because in the intact ECM the proteoheparan sulphate may first need to be liberated from its interaction with various proteins (Lindahl & H66k, 1978) . Proteolytic activity may thus facilitate the accessibility of the proteoglycan for an effective endoglycosidase action. Since low-metastatic Eb cells only produce the protease, but not the endoglycosidase, it may be that due to its size and high negative charge the proteoheparan sulphate itself still impedes tumour cell invasion. Therefore, it seems that the production of an ECM-proteoheparan sulphatespecific endoglycosidase is a pivotal factor for the invasive capacity of a tumour cell. This hypothesis is corroborated by the absence of endoglycosidase activity in the low-metastatic, plastic-adherent variant ESb-MP which is otherwise closely related to the metastatic ESb cells and expresses similar serine proteases (Schirrmacher et al., 1987) . Furthermore, since cell surface proteoheparan sulphate was not degraded, it is likely that the tumour cell-derived endoglycosidase activity is not involved in attachment to and penetration of the endothelial cell layer. The different susceptibility of cell surface-and ECM-proteoheparan sulphate to this endoglycosidase may be based on the structural heterogeneity of different species of proteoheparan sulphates (for review see Gallagher et al., 1986) .
From our results and earlier observations , in which successful invasion of vascular endothelium was more associated with morphological deformations of the tumour cells rather than to enzymatic activity, we conclude that the subendothelial ECM is the main target for tumour-associated proteases and endoglycosidases. In addi- propanesulphonate), 7 M Urea, 1 mM PMSF, 1 mM EDTA, pH 7.2 to which a gradient of 0-1 M NaCl (50+50 ml) was added. Fractions of 2.5 ml were collected and analysed for radioactivity (0 0) and conductivity (---, given as M NaCI). Fractions were pooled as indicated and investigated for their susceptibility to heparinase and chondroitinase AC. The pooled fractions of HS I and PCS were contaminated with each other by <22%. Further purification involved CsCl density gradient centrifugation (data not shown) which yielded proteoglycan preparations that were homogenous according to the criteria published elsewhere (Keller & Furthmayr, 1986; Keller et al., 1987). tion, the invasion process may also be more effective in areas where the endothelial cell layer is injured or disturbed in its confluency, so that subendothelial ECM is readily exposed to degradative enzymes of tumour cells. 
